Asthmatx Debuts Alair For Severe Asthma Following PMA Approval
This article was originally published in The Gray Sheet
Executive Summary
Asthmatx is initiating a "focused launch" of its Alair bronchial thermoplasty system after receiving PMA approval April 27, according to CEO Glen French
You may also be interested in...
Boston Sci Controls New Asthma Device Market With Acquisition
Boston Scientific will spend up to $443.5 million to get its hands on the first interventional device to treat asthma and, in the process, hopes to lessen its reliance on a sluggish cardiovascular franchise
Boston Sci Controls New Asthma Device Market With Acquisition
Boston Scientific will spend up to $443.5 million to get its hands on the first interventional device to treat asthma and, in the process, hopes to lessen its reliance on a sluggish cardiovascular franchise
Research In Brief
Alair study: Long-term efficacy of Asthmatx's bronchial thermoplasty system is demonstrated by five-year data from the Asthma Intervention Research (AIR) trial, presented May 19 at the American Thoracic Society annual meeting in New Orleans. Results showed that over five years, the percentage of patients reporting respiratory adverse events remained stable; hospitalizations and ER visits for respiratory symptoms remained stable; pulmonary function remained stable; and there were no incidences of pneumothorax, intubation, mechanical ventilation, cardiac arrhythmias or death as a result of treatment with Alair. The system, which delivers thermal energy to reduce excess airway smooth muscle associated with airway constriction, is the first device-based asthma treatment approved by FDA (1"The Gray Sheet" May 3, 2010)